

Biophytis second AGM to take place on May 28, 2020 without the physical presence of its shareholders

Paris (France), Cambridge (Massachusetts, USA), May 20, 2020, 8:00 a.m. CEST – BIOPHYTIS (Euronext Growth Paris: ALBPS) a clinical-stage biotechnology company specialized in the development of drug candidates for treatment of aged related diseases, amongst which neuromuscular diseases, informs its shareholders that the second combined General Meeting will be held on May 28, 2020 at 11 am. at the offices of Reed Smith LLP, 112 avenue Kléber, 75016 Paris.

As a result of restrictions placed on the movement and gatherings of persons due to the COVID-19 pandemic, the Company's Combined General Meeting will be held behind closed doors without the physical presence of its shareholders, in accordance with the provisions of Article 4 of Order no. 2020-321 of March 25th, 2020.

The notice of meeting, comprising the agenda and the draft resolutions was published in the French official legal bulletin *Bulletin des Annonces Légales Obligatoires* (BALO) n° 60. These notices include information on how to attend and vote at the General Meeting, as well as the vote bulletin.

All of the documents regarding this combined General Meeting are available to shareholders on the Company's website: www.biophytis.com, in the section Investors / General Assembly 2020: <https://www.biophytis.com/en/action/assemblee-generale-2020/>.

Shareholders are strongly encouraged to vote in advance of the shareholder meeting by mail, by appointing the Chairman of the meeting as your proxy or via the secure online platform VOTEACCESS.

On account of the possible effect of the Covid-19 pandemic on postal delivery times, it is recommended to return your voting forms as soon as practicable.

Please note that the voting forms should be submitted no later than :

- For postal votes, the statutory deadlines apply :
 - o May 24 (4-day deadline before the Meeting) for issuing instructions to the proxy holder
 - o May 25 (3-day deadline before the Meeting) for appointing the proxy
- VOTEACCESS :
 - o May 27 at 3 p.m. CEST

The vote of shareholders who submitted their vote via the post, email or the Internet for the first general meeting remains valid and counted for the general meeting on the second call.

Shareholders who did not vote by post or proxy as part of the first combined General Meeting will be invited to send their forms and shareholder certificates:

- (i) By post : CACEIS Corporate Trust, Service Assemblées Générales Centralisées - 14, rue Rouget de L'Isle - 92862 ISSY-LES-MOULINEAUX Cedex 9, or
- (ii) via email: ct-assemblees@caceis.com

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuromuscular diseases.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development in H2 2020.

Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus). The Company has received approval from the Belgian Regulatory Authority (FAMHP) to begin the Phase 2/3 clinical trial (COVA) with Sarconeos (BIO101), evaluating it as a potential treatment for respiratory failure associated with Covid-19. The Company also filed clinical trial applications with the FDA in the US, MHRA in the UK and the French regulatory agency, ANSM in France.

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825).

For more information www.biophytis.com.

Biophytis Contact for Investor Relations

Evelyne Nguyen, CFO

evelyne.nguyen@biophytis.com

Media contact***Citigate Dewe Rogerson***

Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart

biophytis@citigatedewerogerson.com

Tel: +44 (0) 20 7638 9571 / +33 (0)6 59 42 29 35